Next Article in Journal
Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?
Next Article in Special Issue
Utility of the Neonatal Calf Model for Testing Vaccines and Intervention Strategies for Use against Human RSV Infection
Previous Article in Journal
Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate
Article Menu

Export Article

Open AccessArticle
Vaccines 2019, 7(1), 3; https://doi.org/10.3390/vaccines7010003

Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV

1
Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA
2
Department of Genetic Medicine, Weill Cornell Medicine, New York, NY 10065, USA
*
Author to whom correspondence should be addressed.
Received: 1 December 2018 / Revised: 17 December 2018 / Accepted: 22 December 2018 / Published: 29 December 2018
(This article belongs to the Special Issue Vaccines for Respiratory Syncytial Virus)
Full-Text   |   PDF [1812 KB, uploaded 29 December 2018]   |  

Abstract

Respiratory syncytial virus (RSV) is one of the leading causes of lower respiratory tract infection in infants. Immunoprophylaxis with the anti-RSV monoclonal antibody, palivizumab, reduces the risk for RSV-related hospitalizations, but its use is restricted to high-risk infants due to the high costs. In this study, we investigated if genetic delivery of anti-RSV antibody to neonatal mice by chimpanzee adenovirus type 7 expressing the murine form of palivizumab (AdC7αRSV) can provide protection against RSV. Intranasal and intramuscular administration of AdC7αRSV to adult mice resulted in similar levels of anti-RSV IgG in the serum. However, only intranasal administration resulted in detectable levels of anti-RSV IgG in the bronchoalveolar lavage fluid. Intranasal administration of AdC7αRSV provided protection against subsequent RSV challenge. Expression of the anti-RSV antibody was prolonged following intranasal administration of AdC7αRSV to neonatal mice. Protection against RSV was confirmed at 6 weeks of age. These data suggest that neonatal genetic delivery of anti-RSV antibody by AdC7αRSV can provide protection against RSV. View Full-Text
Keywords: respiratory syncytial virus (RSV); immunoprophylaxis; palivizumab; chimpanzee adenovirus type 7 (AdC7); neonate; passive immunization; genetic gene delivery respiratory syncytial virus (RSV); immunoprophylaxis; palivizumab; chimpanzee adenovirus type 7 (AdC7); neonate; passive immunization; genetic gene delivery
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Gomi, R.; Sharma, A.; Wu, W.; Worgall, S. Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV. Vaccines 2019, 7, 3.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top